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Chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, is primarily a disease
of the elderly, with most patients ≥65 years of age and having at least one major comorbidity. Aggressive
chemoimmunotherapy regimens recommended to achieve remission and improve survival in young, fit patients are
often poorly tolerated in elderly and/or less physiologically fit (“unfit”) patients, necessitating alternative treatment
options. Although patient age, fitness, and comorbidities are key considerations in the selection of a treatment
regimen, historically, clinical trials have been limited to young, fit patients by virtue of the ethical concerns
associated with potential end organ toxic effects that could worsen comorbidities. However, the availability of new
therapies promises a shift to a research paradigm that encompasses the identification of optimal treatments for
elderly and unfit patients. Anti-CD20 monoclonal antibody therapy, which overall has improved response rates and
survival in patients with CLL, has only recently been evaluated elderly and unfit patients. B cell-targeted agents such
as the Bruton’s tyrosine kinase inhibitor ibrutinib and the phosphatidylinositol 3-kinase inhibitor idelalisib are the first
of a new generation of oral agents for CLL. Available clinical data suggest that these therapies have the potential
to address the unmet need in elderly and unfit patients with CLL and result in clinical remission, and not merely
symptom palliation and improved quality of life, which, by themselves, are also a reasonable goal.
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Chronic lymphocytic leukemia (CLL) is a lymphoprolif-
erative disorder whose clinical features include the ab-
normal proliferation of mature B cells in peripheral
blood, bone marrow, and lymph nodes [1]. It is the most
common adult leukemia in the Western world [2]; in the
USA, approximately 15,720 new CLL cases and 4600
deaths are expected to have occurred in 2014 [3]. CLL is
primarily a disease of the elderly, with a median age at
diagnosis of approximately 72 years [4, 5] and nearly
70 % of diagnoses in patients ≥65 years of age (Fig. 1a)
[6]. The incidence of CLL increases progressively with
each decade in patients >60 years of age (Fig. 1b) [7],Correspondence: krai@nshs.edu
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(Fig. 2) [8].
Chronic lymphocytic leukemia is currently considered
incurable [1], but in many patients, the disease is indo-
lent. Therefore, even though diagnosis is typically made
early in the disease course [1], therapy is reserved for
those with advanced, symptomatic, or aggressive disease
[9]. Accordingly, patients typically receive their first
treatment at an older age [6], when they may be frail
and have comorbidities that complicate treatment.
Within the current CLL treatment paradigm, there are
important unmet needs in elderly and less physiologic-
ally fit (unfit) patients. This article reviews the evolution
and current status of therapy for CLL, with particular
regard to elderly and unfit patients, and discusses the
potential of B cell-targeted agents.ributed under the terms of the Creative Commons Attribution License (http://
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Fig. 1 Age-related CLL statistics in the USA. a Percentage of US patients by age at CLL diagnosis, 2009 [6]. b Age-specific incidence rates of CLL,







Fig. 2 Comorbidities in patients with CLL [8]. Major comorbidities
include cardiac disease, diabetes mellitus, respiratory disease, and
other malignancy. CLL chronic lymphocytic leukemia
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The clinical course of CLL is heterogeneous [1], and
after a diagnosis is made, staging and prognostic assess-
ment are important to determine the anticipated disease
course and appropriate therapy, if any [1, 10]. Prognostic
factors include basic laboratory parameters (e.g., abso-
lute lymphocyte count, lymphocyte doubling time,
serum lactate dehydrogenase), immunoglobulin heavy
chain status, and cytogenetic profile (e.g., del 13q, del
11q, del 17p, and trisomy 12 status) [1, 11]. Patient char-
acteristics, including age, fitness, functional status, and
comorbidities, are equally important [1, 10, 12]. In re-
lapsed patients, response to first-line treatment should
also be taken into consideration [12].
These principles are reflected in the National Compre-
hensive Cancer Network (NCCN) Clinical Practice
Guidelines (Table 1) [10]. In younger and/or fit patients
with CLL, the goal is to achieve complete remission and
prolong survival [6], and the NCCN guidelines recom-
mend chemoimmunotherapy as first-line treatment. The
combination of with fludarabine, cyclophosphamide, and
Table 1 NCCN-suggested treatment regimensa for CLL [10]
Setting Younger/fit patientsb Elderly/physiologically
unfit patientsc









































HDMP + rituximab Dose-dense rituximab
CLL chronic lymphocytic leukemia, FCR fludarabine, cyclophosphamide, and
rituximab, FR fludarabine and rituximab, HDMP high-dose methylprednisolone,
NCCN National Comprehensive Cancer Network, OFAR oxaliplatin, fludarabine,
cytarabine, and rituximab, PCR pentostatin, cyclophosphamide, and rituximab,
RCHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
aCLL without del 11q or del 17 p; regimens are listed in order of preference
bAge <70 years, or older patients without significant comorbidities
cAge ≥70 years, or younger patients with comorbidities
dIn patients with long response, suggested to re-treat as in first-line therapy
until short response
eAlemtuzumab is no longer commercially available for CLL
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prolong overall survival in patients with CLL [13] and is
the current standard of care [10, 14]. In relapsed/refrac-
tory patients, treatment is guided by the length of re-
sponse to first-line treatment. In patients who had a
long response, it is recommended that first-line treat-
ment be repeated until a short response is obtained,
whereas in patients who had a short response, second-line treatment with ibrutinib, idelalisib ± rituximab
chemoimmunotherapy, ofatumumab, obinutuzumab,
lenalidomide ± rituximab, alemtuzumab ± rituximab,
or high-dose methylprednisolone + rituximab is rec-
ommended [10].
Because aggressive therapy is often poorly tolerated by
older patients and patients who are less physiologically
fit [15], for patients ≥70 years of age or younger patients
with significant comorbidities, the NCCN guidelines rec-
ommend alternative chemoimmunotherapies such as
obinutuzumab + chlorambucil and rituximab + chloram-
bucil as first-line treatment [10]. Similarly, in relapsed/
refractory patients, alternatives such as reduced-dose
FCR and reduced-dose pentostatin with cyclophospha-
mide and rituximab are recommended. The goals of
these less aggressive treatment regimens are to achieve
symptom palliation and maximize quality of life [16].
Obtaining high rates of complete response (CR) in these
patients may necessitate new treatment approaches.Anti-CD20 monoclonal antibody therapy for CLL
Large randomized trials demonstrated significant im-
provement in overall response rate and progression-free
survival (PFS) with addition of rituximab to fludarabine
and cyclophosphamide (FCR regimen) in patients with
previously untreated CLL [13] and relapsed CLL [17].
However, patients in these studies were relatively young
(median age, 61 [13] and 63 years [17]) and fit, such that
benefit in elderly/unfit patients could not be established.
There are few trials in elderly patients with CLL [6],
but some data support the applicability of rituximab-
based regimens in this population. A recent study of
rituximab added to an oral low-dose FC regimen in 30
elderly patients (median age, 75 years) reported a CR of
80 % in frontline patients and 30 % in previously treated
patients, with only mild hematologic toxicity [18]. A
larger study is needed to confirm these promising find-
ings. In a retrospective study in outpatients ≥70 years of
age receiving bendamustine monotherapy versus rituxi-
mab + bendamustine, the overall response rate was 50 %
versus 67 %, respectively, in treatment-naive patients
and 45 % versus 64 % in relapsed/refractory patients,
with no unexpected toxicities [19]. Results of a subgroup
analysis of a phase 2 clinical trial suggest that rituximab
in combination with pentostatin and cyclophosphamide
is effective and tolerable in older (≥70 years) as well as
younger patients [20].
Compared with data from historical trials of rituximab-
based chemoimmunotherapy (rituximab with pentostatin
and cyclophosphamide), recent data for ofatumumab-
based chemoimmunotherapy (ofatumumab, pentostatin,
and cyclophosphamide) are favorable with regard to effi-
cacy and hematologic toxicity in patients with previously
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ized trials comparing these regimens are currently lacking.
Obinutuzumab (formerly GA101) is a glycoengineered
type 2 antibody that, like rituximab, kills cells via bind-
ing to the CD20 antigen. In patients with previously un-
treated CLL and coexisting conditions, most of whom
were >70 years of age, obinutuzumab + chlorambucil
chemoimmunotherapy significantly improved outcomes
(PFS; overall, complete, and molecular response; and
overall survival) compared with rituximab + chlorambu-
cil [22]. In November 2013, the US Food and Drug
Administration approved obinutuzumab for use in com-
bination with chlorambucil in patients with previously
untreated CLL.
Unmet needs in elderly and unfit patients with CLL
Comorbidity, more than age, limits the use of aggressive
chemoimmunotherapy in CLL [6]. However, there is no
standard method to define patient fitness [6]. Eastern Co-
operative Oncology Group (ECOG) [23] and Karnofsky
performance [24] status, although they lack components
to adjust for specific comorbidities, are widely used in the
USA and as entry criteria in CLL clinical trials. NCCN
guidelines recommend that assessment of fitness consider
age and performance status as well as comorbidities,
which can be evaluated using tools and scoring systems
such as the Charlson Comorbidity Index (CCI), Cumula-
tive Illness Rating Scale (CIRS), or National Cancer Insti-
tute (NCI) Comorbidity Index [10]. The CCI derives a
total score based on the presence (0 = absent; 1 = present)
and severity (1 = not ill; 5 = moribund) of 30 comorbid
diseases [25]. It has been used to predict mortality risk in
a variety of medical conditions [26], and Sorror and col-
leagues [27] modified the CCI to develop a hematopoietic
cell transplantation-specific comorbidity index. The
National Institute on Aging and NCI comorbidity index
was developed using the NCI Surveillance, Epidemiology,
and End Results (SEER) program registries to assess co-
morbidity prevalence in patients with cancer ≥65 years of
age [28, 29]. It includes 24 major comorbidity categories
rated on a 4-point severity scale (1 = current medical
management or diagnostic problem; 4 = condition noted;
unknown if history or current) [29]. The CIRS is an in-
strument for rating physical impairment across 6 bodily
systems and 13 organ areas using a 5-point severity scale
(0 = none; 4 = extremely severe) and can be used to assess
current or cumulative illness [30]. Last, the Index of Coex-
istent Disease (ICED) measures comorbidity severity
(5-point scale) across 14 disease categories and related
physical impairment (4-point scale) within 10 functional
areas [31]. The Sorror versions of the CCI and the ICED
are considered most applicable to the CLL population,
although validation in CLL is still lacking [6]. Irrespective
of the method for defining patient fitness, knowledge ofthe presence of comorbidities should be paired with clin-
ical judgment to help guide treatment decisions in elderly
patients with CLL.
There is a clear need for greater representation of eld-
erly, unfit patients in randomized clinical trials of CLL
chemotherapy [32] to assess the therapeutic endpoint,
CR, in this key population. As noted in the NCCN
guidelines, the German CLL Study Group trial of first-
line treatment with fludarabine versus chlorambucil in
patients >65 years of age [33] is the only completed
phase 3 trial that has specifically enrolled elderly patients
with CLL.
Potential role of B cell-targeted agents in CLL
Therapy for CLL is evolving toward targeted approaches
firmly grounded in an understanding of the disease
pathophysiology [34, 35]. The B-cell receptor (BCR) reg-
ulates fundamental B-cell processes, including resting
homeostasis, differentiation, proliferation, and survival
[36]. Ablation of the BCR leads to rapid B-cell apoptosis,
suggesting that it confers a survival signal to B cells [37].
These functions of the BCR are mediated by tonic and
antigen-induced signals, which are transmitted by
various kinases, including Lyn kinase, spleen tyrosine
kinase (SYK), phosphatidylinositol 3-kinase (PI3K),
and Bruton’s tyrosine kinase (BTK), via intracellular
signaling cascades (Fig. 3) [38].
Bruton’s tyrosine kinase, which is overexpressed in
CLL [39], initiates a signaling cascade leading to the acti-
vation of the transcription factors nuclear factor kappa B
and nuclear factor of activated T cells [38]. These tran-
scription factors play an essential role in B-cell prolifera-
tion [40] and survival [41].
PI3K, a phosphatidylinositol lipid kinase, phosphory-
lates lipid second messengers, leading to the recruitment
of a variety of effectors involved in the growth, prolifera-
tion, differentiation, and survival of B cells [42, 43].
Notably, survival of resting, mature B cells is dependent
on a BCR signal mediated by PI3K [44]. PI3K is more
active in B cells of patients with CLL compared with
those of healthy persons [45].
Spleen tyrosine kinase is activated upstream of BTK
and PI3K and has cooperative and overlapping functions
with respect to these kinases, including activation of
phospholipase C gamma 2, an important effector [46].
Downstream effects include the regulation of B-cell acti-
vation, growth, differentiation, and maturation [46].
Modulation of these kinases offers a potential strategy
to address the various perturbations of BCR signaling in
CLL [36, 47]. Ibrutinib (PCI-32765) is an oral, first-in-
class BTK inhibitor indicated for the treatment of CLL
in patients who have received ≥1 prior therapy. In
preclinical in vitro and in vivo studies, ibrutinib inhib-
ited BCR-controlled integrin activation, BCR-activated
Fig. 3 BCR signaling cascades in the a absence and b presence of antigen. Protein kinases are shown in red and the lipid kinase PI3Kδ in blue
[38]. BCR B-cell receptor, BTK Bruton’s tyrosine kinase, Ig immunoglobulin, IKK I kappa B kinase, NF nuclear factor, NFAT nuclear factor of activated
T cells P phosphorylation, PI3Kδ phosphatidylinositol 3-kinase, PKC protein kinase C, PLC phospholipase C, SYK spleen tyrosine kinase. From [38]
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survival of CLL cells [48, 49]. Idelalisib (CAL-101) is
a first-in-class PI3K inhibitor indicated for the treat-
ment of relapsed CLL, in combination with rituximab,
in patients for whom rituximab alone would not be
considered appropriate therapy because of other co-
morbidities. It is selective for the PI3Kδ isoform [45],
which is generally expressed only in leukocytes [50].
In vitro, idelalisib inhibited the tonic PI3K survival
signal and induced apoptosis in multiple B-cell malig-
nancies [45]. It exhibited dose-dependent cytotoxicity
in CLL cells, while sparing T cells and natural killer
cells [45]. These data provide a potential mechanism
of action for clinical activity in CLL without toxicities
associated with off-target effects in nonhematopoietic
cells [45]. Fostamatinib is an oral SYK inhibitor in de-
velopment for B-cell non-Hodgkin lymphoma (NHL)
and CLL [51]. In primary tumor cells of patients with
relapsed CLL, fostamatinib reduced BTK phosphoryl-
ation, activation of downstream effectors, and CLL
cell activation and proliferation [52]. Other kinase
inhibitors in clinical development for CLL include the
PI3K inhibitors TGR-1202 and IPI-145 [53, 54], the
BTK inhibitors CC-292 and ONO-4059 [55, 56], the
SYK inhibitor GS-9973 [57], and the multikinase in-
hibitor dasatinib [58].
An additional investigational molecular target for CLL
therapy is BCL-2, a protein that protects cells from
apoptosis [59]. Inhibition of BCL-2 would allow for pro-
grammed cell death. ABT-199, a first-in-class BCL-2-
selective inhibitor [59], induced apoptosis in CLL cells
[59] and had cell-killing activity in NHL cell lines [60]
while sparing platelets [59, 60]; it also promoted tumor
regression in mouse xenograft models [60]. Preliminary
data in three patients with refractory CLL show rapid
tumor lysis [60].Raising the bar: potential to elevate treatment goals
beyond palliation specifically in the elderly and unfit
Numerous clinical trials in elderly and unfit patients with
CLL are currently ongoing (Table 2). Treatments include
monotherapy (e.g., kinase inhibitor, anti-CD20 monoclonal
antibody) and combination therapy (e.g., kinase inhibitor ±
chemotherapy, kinase inhibitor ± anti-CD20 monoclonal
antibody, anti-CD20 monoclonal antibody ± chemother-
apy). The majority of these trials are in previously un-
treated patients. Results from two trials of B cell-targeted
agents (one trial of ibrutinib and one of idelalisib) in elderly
or unfit patients have been reported.
First-line ibrutinib therapy
A phase 1b/2, open-label, US, multicenter trial evaluated
the clinical safety and efficacy of ibrutinib as first-line
treatment in patients ≥65 years of age with CLL or small
lymphocytic lymphoma (SLL) [61]. Patients received
28-day cycles of once-daily ibrutinib 420 or 840 mg, but
the 840-mg cohort was closed because of demonstration
of comparable activity of the doses in another study. The
primary endpoint was safety, assessed by adverse events
(AEs) and the study design was such that validation of
safety endpoints would result in study termination. The
proportion of patients that achieved an overall response,
PFS, and the long-term tolerability and pharmaco-
dynamics of ibrutinib were secondary endpoints.
A total of 31 patients (CLL, n = 29) were enrolled, with
a median age of 71 years; 74 % of patients were >70 years
of age. Median time from initial diagnosis to study entry
was 57.3 months; based on ECOG performance status
(0, 74 %; 1, 26 %), patients were relatively fit, despite hav-
ing several comorbidities. Median treatment duration was
21.0 months, during which relative dose intensity was
98.9 %. The most common overall AEs were diarrhea
(68 %), nausea (48 %), and fatigue (32 %), and the most
Table 2 Ongoing key clinical trials in elderly or unfit patients with CLL
Study Design Treatment Patients Primary outcome
NCT01722487 Phase 3, randomized, multicenter,
open-label (RESONATE-2)
Ibrutinib vs chlorambucil Frontline CLL/SLL, ≥65 years PFS
NCT01886872 Phase 3, randomized, multicenter,
open-label
Ibrutinib vs ibrutinib + rituximab
vs bendamustine + rituximab
Frontline CLL, ≥65 years PFS
NCT01203930 Phase 2, single-arm, multicenter,
open-label
Idelalisib or idelalisib + rituximab Frontline CLL/SLL, ≥65 years OR
NCT00645606 Phase 3, randomized, multicenter,
open-label
Rituximab vs observation as
maintenance after FCR
Frontline CLL, >65 years PFS
NCT01263704 Phase 2, single-arm, multicenter,
open-label
Rituximab + low dose fludarabine +
cyclophosphamide
Frontline CLL, ≥65 years OR
NCT01832922 Phase 1, nonrandomized, multicenter,
open-label, dose-ranging
Bendamustine + rituximab CLL/SLL, multiple comorbidities ±
renal insufficiency
AEs, MTD
NCT02015208 Phase 1/2, single-center, single-arm,
open-label
Ruxolitinib Frontline CLL, ≥65 years
or ≥18 years with 17p
deletion
OR
NCT01444716 Phase 2, single-center, single-arm,
open-label
Ofatumumab Frontline CLL, ≥65 years, unfit OR





Poor-risk CLL, >55 years OR, rate of MRD-
negative status
AE adverse event, CLL chronic lymphocytic leukemia, CR complete response, FCR fludarabine, cyclophosphamide, rituximab, MRD minimum residual disease, MTD
maximum tolerated dose, OR overall response, OS overall survival, PFS progression-free survival, PS performance status, SLL small lymphocytic lymphoma
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sion (6 %). There was one grade 4 AE (thrombocytopenia)
and no grade 5 AEs. Two patients discontinued because
of AEs (grade 3 fatigue, grade 2 viral infection). The over-
all response rate was 71 %, with 13 % of patients achieving
a CR. Exploratory subgroup analyses showed no differ-
ences in overall response, including in patients ≥70 and
<70 years of age and in patients with and without high-
risk cytogenetics. At 24 months, PFS and overall survival
were 96.3 and 96.6 %, respectively. Median PFS was not
reached, as only one patient progressed during the follow-
up period (Fig. 4). Twenty-six patients (84 %) continued in
the optional long-term extension study, the results of
which have not yet been reported.
Two phase 3, randomized, open-label trials of ibrutinib
in patients ≥65 years of age are currently ongoing (Table 2).
These include a trial of rituximab + bendamustine, rituxi-
mab + ibrutinib, and ibrutinib monotherapy in patients
with previously untreated CLL (NCT01886872) and a mul-
ticenter trial of ibrutinib versus chlorambucil in patients
with previously untreated CLL or SLL (NCT01722487).
Idelalisib + rituximab in previously treated CLL
A pivotal phase 3, randomized, double-blind, placebo-
controlled trial was undertaken to evaluate the safety
and efficacy of idelalisib + rituximab versus placebo +
rituximab in previously treated patients with progres-
sive CLL who were unsuitable for cytotoxic therapy
(decreased renal function, previous therapy-induced
myelosuppression, or major coexisting illness CIRSscore >6 for illnesses unrelated to CLL) [62]. Patients were
stratified based on deletion/mutation status and randomly
assigned to treatment with idelalisib (150 mg twice daily) +
rituximab or placebo + rituximab.
Of the 220 patients enrolled, 78 % were ≥65 years of
age, 85 % had a CIRS score >6 (median score, 8), and
40 % had at least moderate renal dysfunction; high-risk
cytogenetics were common. Patients had received a me-
dian of three prior regimens. Median on-study treatment
duration was 3.8 months for the idelalisib group and
2.9 months for placebo (not significant). At 24 weeks,
PFS, the primary endpoint, was significantly higher in
the idelalisib group compared with the placebo group
(93 vs 46 %; hazard ratio (95 % CI), 0.15 (0.08–0.28); un-
adjusted P < 0.001). Median PFS was not reached in the
idelalisib group, whereas it was 5.5 months in the pla-
cebo group (Fig. 5a). The treatment effect was similar in
all prespecified subgroups, including patients <65 ver-
sus ≥65 years of age and those with high-risk cyto-
genetics and without high-risk cytogenetics. The idelalisib
group also demonstrated significant improvement versus
placebo in the overall response rate (81 13 %; P < 0.001; all
responses were partial responses) and the lymph node re-
sponse rate (93 versus 4 %; P < 0.001). The rate of
12-month overall survival was 92 % with idelalisib and
80 % with placebo (P = 0.02); median overall survival had
not been reached at the time of the analysis (Fig. 5b).
The most common AEs were pyrexia, fatigue, and
nausea; rates were 29, 24, and 24 %, respectively, with
idelalisib + rituximab and 16, 27, and 21 % with placebo +
Fig. 4 Phase 1b/2 trial of ibrutinib monotherapy in elderly patients
with CLL/SLL [61]. a Progression-free survival. b Overall survival. + =
censored. CLL chronic lymphocytic leukemia, SLL small lymphocytic
lymphoma. Reproduced with permission from [61]
Fig. 5 Phase 3 trial of idelalisib + rituximab versus rituximab
monotherapy in patients with relapsed CLL and clinically significant
coexisting medical conditions [62]. a Progression-free survival. b
Overall survival. CLL chronic lymphocytic leukemia. Reproduced with
permission from [62]
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sib + rituximab were diarrhea (4 %), pyrexia (3 %), and
fatigue (3 %); rates were 0, 1, and 2 %, respectively,
with placebo + rituximab. With idelalisib + rituximab,
incidences of grade 3/4 anemia, neutropenia, and
thrombocytopenia were 5, 34, and 10 %, respectively,
compared with 14, 22, and 16 % for placebo + rituxi-
mab. Transaminase elevations were more common
with idelalisib + rituximab (all grade, 35 %; grade 3/4,
5 %) than with placebo + rituximab (all grade, 19 %;
grade 3/4, 1 %); however, no patients discontinued
therapy for these laboratory abnormalities. AE-related
discontinuations were infrequent in both groups (ide-
lalisib + rituximab, 8 % (mainly gastrointestinal and
skin disorders); placebo + rituximab, 10 % (mainly in-
fections and respiratory disorders)). Although long-
term use needs to be evaluated, these data suggest
that idelalisib + rituximab may be a treatment option
for this difficult-to-treat population that is less able to
undergo standard chemotherapy. A phase 2 study
comparing the safety and efficacy of idelalisib mono-
therapy with idelalisib + rituximab in elderly patients
(≥65 years of age) with previously untreated CLL or
SLL is currently underway (NCT01203930).Conclusions
Chronic lymphocytic leukemia is most common in older
patients, with approximately 70 % of diagnoses in
patients ≥65 years of age [6], and first treatment typically
occurs at an advanced age when many patients have
multiple comorbidities [4, 5, 7, 8]. Although age and
comorbidity are recognized as important considerations
in prognostic assessment and choice of therapy, historic-
ally, clinical trials have excluded elderly and unfit
patients because of legitimate ethical concerns regarding
potential toxic effects in vital organs and worsening of
comorbidity. However, with the development of oral
therapies that are relatively nontoxic, CLL oncology is at
the cusp of a paradigm shift whereby clinical trials will
specifically address outcomes in elderly and unfit
patients, who are more representative of the general
CLL population.
Whereas in younger and/or fit patients with CLL,
aggressive chemoimmunotherapy is recommended to
achieve CR and prolong survival [10], such regimens are
Rai Journal of Hematology & Oncology  (2015) 8:85 Page 8 of 9often poorly tolerated by elderly and/or unfit patients,
necessitating an alternative approach. Although the
NCCN guidelines recommend alternative anti-CD20
monoclonal antibody therapy regimens as first-line ther-
apy in elderly and/or unfit patients [10], there have been
few clinical trials of these therapies in this population.
Ibrutinib, a BTK inhibitor, and idelalisib, a PI3K inhibi-
tor, are the first of a new generation of agents to receive
approval for treatment of CLL; several other kinase
inhibitors, including fostamatinib, are in clinical devel-
opment. These agents target BCR signaling, which plays
a key role in B-cell processes fundamental to tumor
growth, including B-cell proliferation and survival, and
offers an important therapeutic target in CLL. Preclinical
data for idelalisib, which is selective for the PI3Kδ
isoform, provide a potential mechanism of action for
clinical activity without toxicities associated with ef-
fects in nonhematopoietic cells. Recently reported tri-
als of ibrutinib and idelalisib support the usefulness
of kinase inhibitors as treatment options in elderly
and unfit patients. The many ongoing trials will help
address unmet need in this difficult-to-treat popula-
tion by defining rates of CR and further informing
optimal treatment strategies.Abbreviations
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